Study of DCC-3014 in Patients With Advanced Tumours

Official Title

Multi-centre, Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumours


This is a multicentre, open-label Phase 1 study of DCC-3014 in patients with advanced solid tumours including but not limited to prostate, breast, gastric, ovarian, and non-small cell lung cancer as well as tumour types with high macrophage content or high expression of CSF-1 such as diffuse-type tenosynovial giant cell tumour. There will be an Escalation Phase and an Expansion Phase in this study

Trial Description

Primary Outcome:

  • Maximum tolerated dose
  • Incidence of Adverse Events
  • Time to maximum observed concentration of DCC-3014
  • Maximum observed concentration of DCC-3014
  • Trough observed concentration of DCC-3014
  • Area under the concentration-time curve of DCC-3014
  • Half life of DCC-3014
  • Objective response rate (ORR= complete response [CR]+partial response [PR]) (Diffuse type Tenosynovial Giant Cell Tumour [DTGCT] patients Expansion phase only)
  • Duration of response rate (DOR) (DTGCT patients Expansion phase only) Measure time from PR or CR to disease progression or death)
Secondary Outcome:
  • Response rate
  • Range of Motion (ROM)
  • Patient reported outcomes

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society